title: Idiopathic Choroidal Neovascularization: Intraocular Inflammatory Cytokines and the Effect of Intravitreal Ranibizumab Treatment.
abstract: Idiopathic choroidal neovascularization (ICNV) is a disorder that primarily affecting patients younger than 50 years and can cause severe loss of vision. Choroidal abnormalities, especially choroidal inflammation, have been thought to be involved in the pathophysiology of ICNV. However, the exact pathogenesis of ICNV remains unclear. The aim of our study was investigate the levels of 27 inflammatory cytokines in the aqueous humor of eyes with ICNV, and to determine the effect of intravitreal injection of ranibizumab (IVR) on cytokine levels. Significantly higher levels of IL-2, IL-10, IL-15, IL-17, basic FGF, and GM-CSF were observed in patients with ICNV compared with controls. However, only IL-17 levels were significantly higher in patients with ICNV compared with controls after adjusting for axial length. Furthermore, there were significant correlations between the levels of IL-10, IL-17, GM-CSF, and VEGF and the lesion area. Significant changes in visual acuity and central retinal thickness were observed after IVR. Besides VEGF, IVR also significantly reduced the levels of IL-2, IL-10, basic FGF, and IL-12, however, the IL-6 levels were significantly increased. Our results suggest that there may be an involvement of IL-17-related inflammatory processes in the etiology of ICNV.
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Houfa
authors: H
authors: Yin
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Xiaoyun
authors: X
authors: Fang
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Jian
authors: J
authors: Ma
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Min
authors: M
authors: Chen
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Yabo
authors: Y
authors: Yang
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Shenchao
authors: S
authors: Guo
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Zhiqing
authors: Z
authors: Chen
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Zhaoan
authors: Z
authors: Su
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Lei
authors: L
authors: Feng
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Panpan
authors: P
authors: Ye
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Fang
authors: F
authors: Wu
authors: Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
authors: Jinfu
authors: J
authors: Yin
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000276:immunology; D016207:Cytokines / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D016753:Interleukin-10 / Q000378:metabolism; D019409:Interleukin-15 / Q000378:metabolism; D020381:Interleukin-17 / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage* / Q000494:pharmacology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D016207:Cytokines; C508609:IL10 protein, human; C569274:IL15 protein, human; C508594:IL2 protein, human; D019409:Interleukin-15; D020381:Interleukin-17; D007376:Interleukin-2; D016753:Interleukin-10; D000069579:Ranibizumab